drugset
drugset / Trial / NCT00695903

Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia

NCT00695903 ↗

Phase 2 Terminated 38 enrolled Merck & Co., Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The overall goals of this study are to compare the safety and efficacy of daptomycin monotherapy 10 mg/kg/day and vancomycin monotherapy dosed to achieve vancomycin trough levels of 15 to 20 μg/mL for the treatment of methicillin-resistant S. aureus bacteremia (MRSA), including right-sided infective endocarditis (RIE).

Timeline

Start
2008-09-17
Primary completion
2010-08-24
Completion
2010-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Daptomycin Other / unclassified 10 mg/kg Intravenous
Subject Vancomycin Other / unclassified 15 mg/kg Intravenous

Indications

bacterial endocarditis